Merck’s Suvorexant Driving Claims May Get Green Light After Lunesta Re-Label
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA signals comfort with declaring low dose of at least one insomnia product as OK for next-day driving, but suvorexant’s fate will depend on Merck’s data.
You may also be interested in...
Insomnia Drug Development Programs Must Include Driving Studies, FDA Says
Agency will require driving simulation studies for all new sleep aids and is asking sponsors of currently approved products to conduct such trials. FDA is directing zolpidem-containing product manufacturers to make labeling changes based, in part, on driving data submitted for Transcept’s Intermezzo.
Transcept Gains Long-Delayed Approval Of Intermezzo
Indication for insomnia characterized by middle-of-the-night awakening followed by difficulty returning to sleep is a first.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.